Bullous pemphigoid - Pipeline Insight, 2021

Bullous pemphigoid - Pipeline Insight, 2021

  • March 2021 •
  • 60 pages •
  • Report ID: 6042284 •
  • Format: PDF
“Bullous pemphigoid - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 9+ pipeline drugs in Bullous pemphigoid pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Bullous pemphigoid Understanding

Bullous pemphigoid: Overview
Bullous pemphigoid is an autoimmune subepidermal blistering disease. It is a rare skin condition that causes large, fluid-filled blisters. They develop on areas of skin that often flex such as the lower abdomen, upper thighs or armpits. Bullous pemphigoid often presents in people over 80 years of age, and mostly affects people over 50. It can occur in younger adults, but bullous pemphigoid in infants and children is rare. Bullous pemphigoid is the result of an attack on the basement membrane of the epidermis by IgG +/- IgE immunoglobulins (antibodies) and activated T lymphocytes (white blood cells). Bullous pemphigoid causes severe itch and (usually) large, tense fluid-filled blisters, which rupture forming crusted erosions. Histopathologic analysis, Direct immunofluorescence (DIF) studies, and /or Indirect immunofluorescence (IDIF) tests are done to diagnosis of bullous pemphigoid. Treatment for bullous pemphigoid is focused on healing the skin and relieving itching, while minimizing adverse side effects of medications.
"Bullous pemphigoid - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bullous pemphigoid pipeline landscape is provided which includes the disease overview and Bullous pemphigoid treatment guidelines. The assessment part of the report embraces, in depth Bullous pemphigoid commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bullous pemphigoid collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Bullous pemphigoid R&D. The therapies under development are focused on novel approaches to treat/improve Bullous pemphigoid.

Bullous pemphigoid Emerging Drugs Chapters
This segment of the Bullous pemphigoid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bullous pemphigoid Emerging Drugs
• Dupilumab: Regeneron/Sanofi
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor ? (IL-4R?) that inhibits both IL-4 and IL-13 signaling. Dupilumab (Dupixent) is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP. The drug is in Phase III clinical studies for bullous pemphigoid. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. Dupilumab was invented using Regeneron’s proprietary VelocImmune technology. The FDA has granted orphan drug designation to Dupilumab or the treatment of bullous pemphigoid.
• Avdoralimab: Innate Pharma
Avdoralimab (IPH5401) is a complement C5a receptor antagonist (Anti-C5aR-215) recombinant human monoclonal antibody. It specifically binds and blocks C5a receptors (C5aR1) expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils. Avdoralimab is being investigated in Phase II clinical trials for Bullous pemphigoid and COVID-19.
Further product details are provided in the report……..

Bullous pemphigoid: Therapeutic Assessment
This segment of the report provides insights about the different Bullous pemphigoid drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Bullous pemphigoid
There are approx. 10+ key companies which are developing the therapies for Bullous pemphigoid. The companies which have their Bullous pemphigoid drug candidates in the most advanced stage, i.e. Phase III include, Regeneron/Sanofi.
• Phases
This report covers around 9+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Bullous pemphigoid pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bullous pemphigoid: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Bullous pemphigoid therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bullous pemphigoid drugs.

Bullous pemphigoid Report Insights
• Bullous pemphigoid Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bullous pemphigoid Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Bullous pemphigoid drugs?
• How many Bullous pemphigoid drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bullous pemphigoid?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bullous pemphigoid therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bullous pemphigoid and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Regeneron
• Sanofi
• Innate Pharma
• Amgen
• Akari Therapeutics

Key Products
• Dupilumab
• Avdoralimab
• Apremilast
• Nomacopan